var data={"title":"Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B, hepatitis B conjugate vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/441730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562067\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Infanrix Hexa&trade;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562071\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial);</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562136\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Vaccinate preterm infants according to their chronological age from birth. Vaccination usually begins at 2 months, but may be started at 6 weeks of age. Do not administer to infants &lt;6 weeks of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> Infants and Children 6 weeks to 2 years: IM: 0.5 mL per dose; repeat 0.5 mL dose in intervals of at least 1 month for a total of 2 or 3 doses if full term at birth, or a total of 3 doses if preterm (born after at least 24 weeks gestational age)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Use in children previously vaccinated with one or more doses of hepatitis B vaccine:</i> Children who received 1 dose of hepatitis B vaccine at birth (or shortly thereafter) may receive a 3-dose series of Infanrix Hexa beginning at &ge;6 weeks of age. Use in infants who received more than 1 dose of hepatitis B vaccine has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Where immunization against poliovirus is desired, Infanrix Hexa may be administered instead to infants scheduled to receive concurrent Infanrix (diphtheria, tetanus and acellular pertussis vaccine) and hepatitis B vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster immunization:</b> IM: 0.5 mL dose administered at 12 to 23 months of age if the patient received 3-dose primary series or at 11 to 13 months of age if the patient received 2-dose primary series. Booster dose should be administered at least 6 months after the last priming dose and is intended for infants who have received a full primary vaccination course of each component of Infanrix Hexa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Dosing delays should not interfere with the final immunity achieved with Infanrix Hexa. Regardless of the time that elapses between doses, it is not necessary to restart the vaccination series.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562140\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:0em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix Hexa: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg], HBsAg 10 mcg, type 1 poliovirus 40 D antigen units, type 2 poliovirus 8 D antigen units and type 3 poliovirus 32 D antigen units, <i>Haemophilus</i> b capsular polysaccharide 10 mcg [bound to tetanus toxoid ~25 mcg] per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate (trace amounts), polymyxin B (trace amounts), polysorbate 20, polysorbate 80, and yeast protein &le;5%; Pediarix vaccine used to reconstitute Hib forms Infanrix Hexa]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562077\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562137\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Administer by IM injection only, preferably in the anterolateral aspects of the thigh or the deltoid muscle of the upper arm. Do not administer intravenously or subcutaneously. Do not inject into the gluteal area (suboptimal hepatitis B immune response) or areas where major nerve trunks may be located. Fractional dosing (use of reduced volume) is not recommended. Rotate injection sites when completing vaccination series. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562072\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and <i>Haemophilus</i> b disease prevention: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Active primary immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by <i>Haemophilus influenzae</i> type b in infants and children 6 weeks to 2 years of age; booster immunization (at 12 to 23 months) in infants who previously received a full primary vaccination course of each component of the vaccine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">According to the National Advisory Committee on Immunization (NACI), the vaccine may be administered to children 2 years to &lt;7 years if necessary (NACI 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562066\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix Hexamay be confused with Infanrix or Infanrix-Polio</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Infanrix Hexa is supplied in two vials, one containing DTaP-HepB-IPV liquid and one containing Hib powder, which must be mixed together in order to administer the recommended vaccine components. Errors have occurred when both vials have not been used or are mixed improperly, ensure proper preparation before administering.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562105\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (83%), hypersomnia (63%), sleep disorder (sleeping decreased: 51%), emotional lability (crying: 43%), fatigue, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (49%), diarrhea (36%), vomiting (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (49%), pain at injection site (43%), swelling at injection site (36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&ge;38&deg;C [100.4&deg;F]: 56%; &gt;39.5&deg;C [103.1&deg;F]*)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Induration at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, apnea, bronchitis, bronchospasm, cellulitis (inflammatory cellulitis without bacterial infection), collapse, cough, dermatitis, drowsiness, edema (diffuse edema of injected limb), hypersensitivity reaction (including anaphylactoid reaction and anaphylaxis), hypotonic/hyporesponsive episode, injection-site vesicle, lymphadenopathy, seizure (including febrile seizure), skin rash, thrombocytopenia, upper respiratory tract infection, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562075\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of vaccine or formulation; encephalopathy of unknown etiology within 1 week following prior vaccination with a pertussis-containing vaccine; moderate or severe acute febrile illness or acute infection; children &gt;7 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562076\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reactions from previous dose: Carefully consider use in patients with history of any of the following effects from previous administration of whole-cell DTP or acellular pertussis vaccine: Fever &ge;105&deg;F (40.5&deg;C) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; shock or collapse within 48 hours. Use is contraindicated in patients who have had encephalopathy within 7 days of a previous pertussis-containing vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]; NACI 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: Use is contraindicated in patients with moderate or severe acute illness (with or without fever); in general, vaccines may be administered to patients with mild acute illness (with or without fever) (NACI 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]; NACI 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Guillain-Barr&eacute; syndrome: Patients who develop Guillain-Barre syndrome (GBS) within 6 weeks of receipt of a vaccine containing tetanus-toxoid should not receive any further doses; patients who develop GBS &gt;6 weeks after immunization may receive subsequent doses of the vaccine (NACI 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Use for completion of hepatitis B vaccination series in infants born to HBsAG-positive mothers and previously vaccinated with hepatitis B immune globulin or born to mothers of unknown status, has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurologic disorders: Use with caution in patients with personal or immediate family (parent, sibling) history of progressive neurologic disease, or conditions predisposing to seizures; where appropriate, consider deferring immunization until health status can be assessed and condition stabilized. Antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever (may occur within 2 to 3 days).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Poliomyelitis: Defer administration during outbreaks of poliomyelitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the NACI recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events (NACI 2016). An increased incidence of febrile reactions, convulsions (with or without fever) and hypotonic hyporesponsive episode have been observed with concomitant use of Infanrix hexa and pneumococcal conjugate vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids); may have a reduced response to vaccination. May be used in patients with HIV infection. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premature infants: May be administered to infants born prematurely beginning at chronological age of 6 weeks; decreased immune response may be observed and the degree of clinical protection is unknown. Infants born &le;28 weeks gestation may be at greater risk for apnea; monitor respiratory function closely for 2 to 3 days following vaccination, particularly with history of respiratory immaturity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: Formulation may contain aluminum.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Formulation contains trace amounts of neomycin; use caution in patients with prior hypersensitivity to neomycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polymyxin B: Formulation contains trace amounts of polymyxin B; use caution in patients with prior hypersensitivity to polymyxin B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299217\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12608708\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16462&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine: May diminish the therapeutic effect of Tetanus Toxoids Vaccines. Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562073\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562074\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562139\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs/symptoms of hypersensitivity for 30 minutes after administration; respiratory function for 2 to 3 days following vaccination of infants born prematurely. Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562132\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes active immunity to diphtheria, tetanus, pertussis, hepatitis B, poliovirus (types 1, 2, and 3), and <i>Haemophilus influenzae</i> type B by inducing production of specific antibodies and antitoxins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11562126\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Onset: Immune response observed to all components 1 month following the 3-dose series </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23670090\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Hexacima (LV);</li>\n      <li>Hexaxim (SA, SG);</li>\n      <li>Infanrix Hexa (AE, AR, AT, AU, BE, CH, CL, CY, CZ, DE, ES, GR, HK, HR, ID, IE, IL, IT, KW, LB, LK, LT, MT, MX, MY, NL, NZ, PE, PH, PL, PT, QA, RO, SA, SE, TH, TR, UA, VE, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006. Available at https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html. Accessed April 19, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infanrix Hexa (combined diphtheria and tetanus toxoids, acellular pertussis, hepatitis B [recombinant], inactivated poliomyelitis and adsorbed conjugated <i>Haemophilius influenzae</i> type b vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ome&ntilde;aca F, Garcia-Sicilia J, Garc&iacute;a-Corbeira P, et al, &ldquo;Response of Preterm Newborns To Immunization With a Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B Virus-Inactivated Polio and Haemophilus Influenzae Type B Vaccine: First Experiences and Solutions To a Serious and Sensitive Issue,&rdquo; <i>Pediatrics</i>, 2005, 116(6):1292-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/16322149/pubmed\" target=\"_blank\" id=\"16322149\">16322149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics. Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures. <i>Pediatrics.</i> 2008;121(6):1281-1286.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphtheria-tetanus-toxoids-acellular-pertussis-inactivated-poliovirus-haemophilus-influenzae-type-b-hepatitis-b-conjugate-vaccine-drug-information/abstract-text/18519501/pubmed\" target=\"_blank\" id=\"18519501\">18519501</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16462 Version 81.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11562067\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F11562071\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F11562136\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11562140\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11562077\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11562137\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F11562072\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11562066\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11562105\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11562075\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11562076\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299217\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F12608708\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11562073\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11562074\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11562139\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11562132\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11562126\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23670090\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16462|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}